BioNTech Results Presentation Deck
Q3 2021 and 9M 2021 COVID-19 Vaccine Deliveries Drove Revenue Growth
€6,021.6m
33
COVID-19 vaccine revenues
€6,040.1m
€4,358.5m
€1,350.8m
€312.3m
€18.5m Q3 2021
€13,348.1m
€10,202.7m
€2,586.2m
€514.3m
-€44.9m
Commercial revenues - identified revenue streams
COVID-19 vaccine revenues
€13,303.2m
9M 2021
*Represents an estimated figure based on preliminary data shared between Pfizer and BioNTech.
Changes in share of the collaboration partner's gross profit will be recognized prospectively.
Graphic is for illustration only.
Share of gross profit from COVID-19 vaccine
sales in the Pfizer and Fosun territory (net
position) and sales milestones (€17.0m for Q3
2021 and €432.8m for 9M 2021, respectively)*
Direct COVID-19 vaccine sales to customers in
BioNTech's territory
Sales to collaboration partners of products
manufactured by BioN Tech
Other sales (mainly JPT and IMFS business)
BIONTECHView entire presentation